Sarepta Therapeutics (SRPT) Restructuring Costs (2020 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Restructuring Costs of $1.5 million for Q4 2025, down 96.3% quarter-over-quarter from $40.5 million in Q3 2025.
Sarepta Therapeutics (SRPT) Restructuring Costs (2020 - 2026) Analysis & Trends
Sarepta Therapeutics' Restructuring Costs history runs 2 years deep, the most recent figure standing at $1.5 million for Q4 2025.
- In Q4 2025, Restructuring Costs changed N/A year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $42.0 million (changed N/A YoY), while the FY2025 annual figure was $42.0 million, changed N/A from the prior year.
- Restructuring Costs for Q4 2025 stood at $1.5 million, down from $40.5 million in the prior quarter.
- The five-year high for Restructuring Costs was $40.5 million in Q3 2025, with the low at $1.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.00 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Sep 30, 2025 | 40.50 Mn |
| Sep 30, 2020 | 45.00 Mn |